Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Bayer makes 'substantial progress' in Roundup cancer lawsuits, mediator says

Published 09/11/2020, 22:10
Updated 09/11/2020, 22:15
© Reuters. FILE PHOTO: Monsanto Co's Roundup shown for sale in California

© Reuters. FILE PHOTO: Monsanto Co's Roundup shown for sale in California

By Jonathan Stempel

(Reuters) - A court-appointed mediator on Monday said Bayer AG (DE:BAYGn) has made "substantial progress" toward resolving tens of thousands of remaining claims that its Roundup weedkiller causes cancer.

The mediator Kenneth Feinberg spoke at a Zoom hearing in San Francisco federal court, where a judge still oversees nearly 2,000 unresolved cases over glyphosate-based Roundup, which Bayer acquired with its purchase of Monsanto (NYSE:MON). Other cases are in state courts.

"We're not there yet but we are certainly making substantial progress," said Feinberg, who oversaw compensation programs for victims of the Sept. 11 attacks and 2010 Gulf of Mexico oil spill. "It's just a question of when and how quickly they'll get resolved."

U.S. District Judge Vince Chhabria had previously paused the federal litigation and given Bayer until Nov. 2 to settle.

Bayer has said 1,861 of the 3,787 plaintiffs in that litigation had not settled. Chhabria did not extend the stay, meaning some cases could move toward possible trials.

"I'm not interested in having such an elongated schedule for the adjudication of these cases," he said.

Bayer has said Roundup is safe for human use.

The German company inherited liability for the lawsuits when it bought Monsanto for $63 billion (£48 billion) in June 2018, becoming the world's largest supplier of seeds and pesticides. Its shares have since fallen 54%.

In June, Bayer projected it would pay up to $10.9 billion to resolve Roundup litigation, mostly for existing claims and $1.25 billion for future claims.

Last week, it increased the projected cost of future claims to $2 billion, and took a 9.25 billion euro ($10.9 billion) writedown in its crop science business.

It also said it had resolved roughly 88,500 out of an estimated 125,000 filed and unfiled Roundup claims.

Bayer lost three Roundup trials in 2018 and 2019. In October, the California Supreme Court declined to hear its appeal from a $20.5 million award in favor of school groundskeeper Dewayne Johnson for his non-Hodgkin's lymphoma.

© Reuters. FILE PHOTO: Monsanto Co's Roundup shown for sale in California

The case is In re Roundup Products Liability Litigation, U.S. District Court, Northern District of California, No. 16-md-02741.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.